Interleukin-2 induces antigen reactive T cell lines to secrete BCGF-I

M. Howard, L. Matis, Thomas Malek, E. Shevach, W. Kell, D. Cohen, K. Nakanishi, W. E. Paul

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Antigen-activated T lymphocytes produce within 24 h of stimulation a factor that is distinguishable biochemically and functionally from the B cell costimulating growth factor, BCGF-I, originally identified in induced EL4 supernatants: Supernatants from antigen-stimulated T cell lines are not directly mitogenic for resting B cells, but synergize in an H-2-unrestricted manner with anti-Ig activated B cells to produce polyclonal proliferation but not antibody-forming-cell development; biochemical studies reveal the B cell co-stimulating factor present in antigen-stimulated T cell line supernatants is identical by phenyl Sepharose chromatography and isoelectric focusing (IEF) to EL4 supernatant BCGF-I. We thus conclude that normal T cells produce BCGF-I in response to antigenic stimulation. Analysis of the mechanism of BCGF-I production by antigen-stimulated T cells showed that optimum amounts of BCGF-I were obtained as quickly as 24 h post-stimulation, and that the factor producing cells in the T cell line investigated bore the Lyt-1+2- phenotype. As few as 106 T cells produced sufficient BCGF-I to support the proliferation of 5 x 104 purified anti-Ig activated T cells. Finally, the activation of normal T cell lines to produce BCGF-I required either antigen presented in the context of syngeneic antigen-presenting cells (APC) or interleukin 2 (IL-2).

Original languageEnglish
Pages (from-to)2024-2039
Number of pages16
JournalJournal of Experimental Medicine
Volume158
Issue number6
StatePublished - Dec 1 1983
Externally publishedYes

Fingerprint

Interleukin-2
T-Lymphocytes
Antigens
Cell Line
B-Lymphocytes
Agarose Chromatography
Isoelectric Focusing
Antigen-Presenting Cells
Intercellular Signaling Peptides and Proteins
Phenotype
Antibodies

ASJC Scopus subject areas

  • Immunology

Cite this

Howard, M., Matis, L., Malek, T., Shevach, E., Kell, W., Cohen, D., ... Paul, W. E. (1983). Interleukin-2 induces antigen reactive T cell lines to secrete BCGF-I. Journal of Experimental Medicine, 158(6), 2024-2039.

Interleukin-2 induces antigen reactive T cell lines to secrete BCGF-I. / Howard, M.; Matis, L.; Malek, Thomas; Shevach, E.; Kell, W.; Cohen, D.; Nakanishi, K.; Paul, W. E.

In: Journal of Experimental Medicine, Vol. 158, No. 6, 01.12.1983, p. 2024-2039.

Research output: Contribution to journalArticle

Howard, M, Matis, L, Malek, T, Shevach, E, Kell, W, Cohen, D, Nakanishi, K & Paul, WE 1983, 'Interleukin-2 induces antigen reactive T cell lines to secrete BCGF-I', Journal of Experimental Medicine, vol. 158, no. 6, pp. 2024-2039.
Howard M, Matis L, Malek T, Shevach E, Kell W, Cohen D et al. Interleukin-2 induces antigen reactive T cell lines to secrete BCGF-I. Journal of Experimental Medicine. 1983 Dec 1;158(6):2024-2039.
Howard, M. ; Matis, L. ; Malek, Thomas ; Shevach, E. ; Kell, W. ; Cohen, D. ; Nakanishi, K. ; Paul, W. E. / Interleukin-2 induces antigen reactive T cell lines to secrete BCGF-I. In: Journal of Experimental Medicine. 1983 ; Vol. 158, No. 6. pp. 2024-2039.
@article{1440c02501394010948f2644364ecf77,
title = "Interleukin-2 induces antigen reactive T cell lines to secrete BCGF-I",
abstract = "Antigen-activated T lymphocytes produce within 24 h of stimulation a factor that is distinguishable biochemically and functionally from the B cell costimulating growth factor, BCGF-I, originally identified in induced EL4 supernatants: Supernatants from antigen-stimulated T cell lines are not directly mitogenic for resting B cells, but synergize in an H-2-unrestricted manner with anti-Ig activated B cells to produce polyclonal proliferation but not antibody-forming-cell development; biochemical studies reveal the B cell co-stimulating factor present in antigen-stimulated T cell line supernatants is identical by phenyl Sepharose chromatography and isoelectric focusing (IEF) to EL4 supernatant BCGF-I. We thus conclude that normal T cells produce BCGF-I in response to antigenic stimulation. Analysis of the mechanism of BCGF-I production by antigen-stimulated T cells showed that optimum amounts of BCGF-I were obtained as quickly as 24 h post-stimulation, and that the factor producing cells in the T cell line investigated bore the Lyt-1+2- phenotype. As few as 106 T cells produced sufficient BCGF-I to support the proliferation of 5 x 104 purified anti-Ig activated T cells. Finally, the activation of normal T cell lines to produce BCGF-I required either antigen presented in the context of syngeneic antigen-presenting cells (APC) or interleukin 2 (IL-2).",
author = "M. Howard and L. Matis and Thomas Malek and E. Shevach and W. Kell and D. Cohen and K. Nakanishi and Paul, {W. E.}",
year = "1983",
month = "12",
day = "1",
language = "English",
volume = "158",
pages = "2024--2039",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "6",

}

TY - JOUR

T1 - Interleukin-2 induces antigen reactive T cell lines to secrete BCGF-I

AU - Howard, M.

AU - Matis, L.

AU - Malek, Thomas

AU - Shevach, E.

AU - Kell, W.

AU - Cohen, D.

AU - Nakanishi, K.

AU - Paul, W. E.

PY - 1983/12/1

Y1 - 1983/12/1

N2 - Antigen-activated T lymphocytes produce within 24 h of stimulation a factor that is distinguishable biochemically and functionally from the B cell costimulating growth factor, BCGF-I, originally identified in induced EL4 supernatants: Supernatants from antigen-stimulated T cell lines are not directly mitogenic for resting B cells, but synergize in an H-2-unrestricted manner with anti-Ig activated B cells to produce polyclonal proliferation but not antibody-forming-cell development; biochemical studies reveal the B cell co-stimulating factor present in antigen-stimulated T cell line supernatants is identical by phenyl Sepharose chromatography and isoelectric focusing (IEF) to EL4 supernatant BCGF-I. We thus conclude that normal T cells produce BCGF-I in response to antigenic stimulation. Analysis of the mechanism of BCGF-I production by antigen-stimulated T cells showed that optimum amounts of BCGF-I were obtained as quickly as 24 h post-stimulation, and that the factor producing cells in the T cell line investigated bore the Lyt-1+2- phenotype. As few as 106 T cells produced sufficient BCGF-I to support the proliferation of 5 x 104 purified anti-Ig activated T cells. Finally, the activation of normal T cell lines to produce BCGF-I required either antigen presented in the context of syngeneic antigen-presenting cells (APC) or interleukin 2 (IL-2).

AB - Antigen-activated T lymphocytes produce within 24 h of stimulation a factor that is distinguishable biochemically and functionally from the B cell costimulating growth factor, BCGF-I, originally identified in induced EL4 supernatants: Supernatants from antigen-stimulated T cell lines are not directly mitogenic for resting B cells, but synergize in an H-2-unrestricted manner with anti-Ig activated B cells to produce polyclonal proliferation but not antibody-forming-cell development; biochemical studies reveal the B cell co-stimulating factor present in antigen-stimulated T cell line supernatants is identical by phenyl Sepharose chromatography and isoelectric focusing (IEF) to EL4 supernatant BCGF-I. We thus conclude that normal T cells produce BCGF-I in response to antigenic stimulation. Analysis of the mechanism of BCGF-I production by antigen-stimulated T cells showed that optimum amounts of BCGF-I were obtained as quickly as 24 h post-stimulation, and that the factor producing cells in the T cell line investigated bore the Lyt-1+2- phenotype. As few as 106 T cells produced sufficient BCGF-I to support the proliferation of 5 x 104 purified anti-Ig activated T cells. Finally, the activation of normal T cell lines to produce BCGF-I required either antigen presented in the context of syngeneic antigen-presenting cells (APC) or interleukin 2 (IL-2).

UR - http://www.scopus.com/inward/record.url?scp=0021051785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021051785&partnerID=8YFLogxK

M3 - Article

C2 - 6606015

AN - SCOPUS:0021051785

VL - 158

SP - 2024

EP - 2039

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 6

ER -